OXFORD, U.K., July 13 /PRNewswire/ -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) announces the initiation of a new US clinical study with Vevesca (OGT 918) in type 1 Gaucher disease at New York University School of Medicine (``NYU''). The clinic is part of NYU's comprehensive Gaucher disease programme and is one of the world's leading centres of excellence for the diagnosis and treatment of Gaucher disease.
The study is being conducted in the Gaucher Clinic at NYU by Dr Gregory M. Pastores and Dr Edwin H. Kolodny. Dr Pastores is Associate Director and Dr Kolodny is Director of the Neurogenetics Unit of the School, which has extensive experience in the management of patients with lysosomal storage disorders. Dr Pastores has published key scientific papers on research into Gaucher disease and also serves on the Medical Advisory Board of the US National Gaucher Foundation (``NGF'').
The principal investigator, Dr Pastores, commented, ``We are pleased to have the opportunity to investigate the safety and effectiveness of Vevesca in our patients, and hope to build on the encouraging results that have been published so far.''
Dr Chris Moyses, Clinical and Development Director of OGS, said, ``Vevesca has been developed in an international programme involving leaders in the clinical investigation of glycolipid storage disorders. OGS is delighted now to be working with Dr Pastores and NYU. The study will enroll up to 14 patients with type 1 Gaucher disease who will receive 1 year of treatment with Vevesca monotherapy, complementing previous monotherapy data on a cohort of 28 patients published in The Lancet. The study will also include a proteomic marker analysis. This is the first of a series of planned studies reflecting OGS' ongoing commitment to the treatment of Gaucher disease''... |
